A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients

Thomas Stephen Kickler, Hayden G. Braine, Steven Piantadosi, Paul Michael Ness, Jay H. Herman, Kate Rothko

Research output: Contribution to journalArticle

Abstract

In a placebo-controlled, randomized blinded study, we evaluated the efficacy of intravenous gammaglobulin (IV-IgG) in alloimmunized thrombocytopenic patients. IV-IgG was administered at a dose of 400 mg/kg for 5 days. An incompatible platelet transfusion from the same donor was used before and after treatment. Seven patients received IV-IgG and five patients received placebo. Although platelet recovery in 1 to 6 hours was satisfactory in five patients after IV-IgG treatment, 24-hour survival was not improved in most patients. None of the patients receiving the placebo achieved satisfactory 1-hour platelet-corrected count increments (CCIs). By t test, the posttreatment mean values 1 hour after transfusion CCIs in the IV-IgG group were significantly greater than in the control group (8,413 v 1,050, P <.007). Using a regression model to adjust for any distributional assumptions of the study population, the parameter estimate for IV-IgG treatment was positive, indicating that IV-IgG treatment is associated with higher CCIs. Although IV-IgG may improve 1-hour platelet recovery, clinical benefit was not demonstrated since 24-hour survival was not improved. IV-IgG treatment before unmatched platelet transfusions should not be considered as a replacement for HLA-compatible platelets in alloimmunized patients.

Original languageEnglish (US)
Pages (from-to)313-316
Number of pages4
JournalBlood
Volume75
Issue number1
StatePublished - Jan 1 1990

Fingerprint

Randomized Controlled Trials
Immunoglobulin G
Placebos
Platelets
Platelet Transfusion
Blood Platelets
Therapeutics
Recovery
Survival
Platelet Count
Tissue Donors
Control Groups
Population

ASJC Scopus subject areas

  • Hematology

Cite this

A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients. / Kickler, Thomas Stephen; Braine, Hayden G.; Piantadosi, Steven; Ness, Paul Michael; Herman, Jay H.; Rothko, Kate.

In: Blood, Vol. 75, No. 1, 01.01.1990, p. 313-316.

Research output: Contribution to journalArticle

Kickler, TS, Braine, HG, Piantadosi, S, Ness, PM, Herman, JH & Rothko, K 1990, 'A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients', Blood, vol. 75, no. 1, pp. 313-316.
Kickler, Thomas Stephen ; Braine, Hayden G. ; Piantadosi, Steven ; Ness, Paul Michael ; Herman, Jay H. ; Rothko, Kate. / A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients. In: Blood. 1990 ; Vol. 75, No. 1. pp. 313-316.
@article{7534b3ac94c64db696ea242832a69be6,
title = "A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients",
abstract = "In a placebo-controlled, randomized blinded study, we evaluated the efficacy of intravenous gammaglobulin (IV-IgG) in alloimmunized thrombocytopenic patients. IV-IgG was administered at a dose of 400 mg/kg for 5 days. An incompatible platelet transfusion from the same donor was used before and after treatment. Seven patients received IV-IgG and five patients received placebo. Although platelet recovery in 1 to 6 hours was satisfactory in five patients after IV-IgG treatment, 24-hour survival was not improved in most patients. None of the patients receiving the placebo achieved satisfactory 1-hour platelet-corrected count increments (CCIs). By t test, the posttreatment mean values 1 hour after transfusion CCIs in the IV-IgG group were significantly greater than in the control group (8,413 v 1,050, P <.007). Using a regression model to adjust for any distributional assumptions of the study population, the parameter estimate for IV-IgG treatment was positive, indicating that IV-IgG treatment is associated with higher CCIs. Although IV-IgG may improve 1-hour platelet recovery, clinical benefit was not demonstrated since 24-hour survival was not improved. IV-IgG treatment before unmatched platelet transfusions should not be considered as a replacement for HLA-compatible platelets in alloimmunized patients.",
author = "Kickler, {Thomas Stephen} and Braine, {Hayden G.} and Steven Piantadosi and Ness, {Paul Michael} and Herman, {Jay H.} and Kate Rothko",
year = "1990",
month = "1",
day = "1",
language = "English (US)",
volume = "75",
pages = "313--316",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "1",

}

TY - JOUR

T1 - A randomized, placebo-controlled trial of intravenous gammaglobulin in alloimmunized thrombocytopenic patients

AU - Kickler, Thomas Stephen

AU - Braine, Hayden G.

AU - Piantadosi, Steven

AU - Ness, Paul Michael

AU - Herman, Jay H.

AU - Rothko, Kate

PY - 1990/1/1

Y1 - 1990/1/1

N2 - In a placebo-controlled, randomized blinded study, we evaluated the efficacy of intravenous gammaglobulin (IV-IgG) in alloimmunized thrombocytopenic patients. IV-IgG was administered at a dose of 400 mg/kg for 5 days. An incompatible platelet transfusion from the same donor was used before and after treatment. Seven patients received IV-IgG and five patients received placebo. Although platelet recovery in 1 to 6 hours was satisfactory in five patients after IV-IgG treatment, 24-hour survival was not improved in most patients. None of the patients receiving the placebo achieved satisfactory 1-hour platelet-corrected count increments (CCIs). By t test, the posttreatment mean values 1 hour after transfusion CCIs in the IV-IgG group were significantly greater than in the control group (8,413 v 1,050, P <.007). Using a regression model to adjust for any distributional assumptions of the study population, the parameter estimate for IV-IgG treatment was positive, indicating that IV-IgG treatment is associated with higher CCIs. Although IV-IgG may improve 1-hour platelet recovery, clinical benefit was not demonstrated since 24-hour survival was not improved. IV-IgG treatment before unmatched platelet transfusions should not be considered as a replacement for HLA-compatible platelets in alloimmunized patients.

AB - In a placebo-controlled, randomized blinded study, we evaluated the efficacy of intravenous gammaglobulin (IV-IgG) in alloimmunized thrombocytopenic patients. IV-IgG was administered at a dose of 400 mg/kg for 5 days. An incompatible platelet transfusion from the same donor was used before and after treatment. Seven patients received IV-IgG and five patients received placebo. Although platelet recovery in 1 to 6 hours was satisfactory in five patients after IV-IgG treatment, 24-hour survival was not improved in most patients. None of the patients receiving the placebo achieved satisfactory 1-hour platelet-corrected count increments (CCIs). By t test, the posttreatment mean values 1 hour after transfusion CCIs in the IV-IgG group were significantly greater than in the control group (8,413 v 1,050, P <.007). Using a regression model to adjust for any distributional assumptions of the study population, the parameter estimate for IV-IgG treatment was positive, indicating that IV-IgG treatment is associated with higher CCIs. Although IV-IgG may improve 1-hour platelet recovery, clinical benefit was not demonstrated since 24-hour survival was not improved. IV-IgG treatment before unmatched platelet transfusions should not be considered as a replacement for HLA-compatible platelets in alloimmunized patients.

UR - http://www.scopus.com/inward/record.url?scp=0025012870&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0025012870&partnerID=8YFLogxK

M3 - Article

C2 - 1688499

AN - SCOPUS:0025012870

VL - 75

SP - 313

EP - 316

JO - Blood

JF - Blood

SN - 0006-4971

IS - 1

ER -